Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRY812 in advanced malignancies
NCT06038058Phase 1Recruiting
- Sponsor
- BioRay Pharmaceutical
- Start
- Oct 2023
- Primary completion
- Aug 2028
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BRY812 in malignant neoplasms (advanced stage), sponsored by BioRay Pharmaceutical. Primary endpoints: Adverse Events, Laboratory Abnormalities and 3 more. Started Oct 2023; status: recruiting.
02
Drugs
BRY812
03
Conditions
malignant neoplasms (advanced stage)
Beyond the preview
Go deeper on NCT06038058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06038058.